|
|
Article: Biogen Idec Cutting Staff To Reduce Costs, Tighten Focus.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Biogen Idec plans to reduce its work force by 17 percent and divest certain assets, including its psoriasis drug, Amevive, to funnel more money into its development pipeline.
The move is intended to cut annual operating expenses between $200 million and $300 million, while boosting external business development activities, such as partnerships, collaborations and acquisitions, said Jose Juves, spokesman for the Cambridge, Mass.-based company, adding that the restructuring plan followed a "broad analysis" of its assets.
"There were areas within the company that we felt were really not providing long-term value," he said. "We also ...
Related newspaper, magazine, and journal articles:
|
|
Article: BIOGEN IDEC CUTTING STAFF TO REDUCE COSTS, TIGHTEN ...
BIOWORLD Today;
September 12, 2005 ;
700+ words
... ... issues. (See BioWorld Today, June 20, 2005.) Biogen Idec also is seeking ... of strength." Biogen Idec reported net income ... effort to position Biogen Idec for the years 2010 ... Juves told BioWorld Today. "It will provide ...
|
|